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The envelope proteins of varicella-zoster virus (VZV) are highly immunogenic and one of the most abundant is glycoprotein
E (gE). However, its immunodominant regions and epitopes have not been identified. In this study, using human sera from
individuals with recent varicella or zoster infections, we have localized antigenic sequences of gE using recombinant hybrid
Ty-virus-like particles (VLPs) carrying overlapping fragments of the gE protein. gE(1–134)–VLPs (particles carrying amino
acids 1–134 of gE) and, to a lesser extent, gE(101–161)–VLPs were found to be the most antigenic when tested by Western
blotting and ELISA. Other fragments of gE (spanning residues 161–623) showed weak or no antigenicity. Pepscan analysis
of human sera on overlapping synthetic peptides representing residues 1–135 of gE revealed that the most antigenic region
was between residues 50 and 135. Three immunodominant sequences (residues 86–105, 116–135, and, to a lesser extent,
56 –75) were detected using sera from both varicella and zoster patients. All sera from varicella, but not zoster, patients
reacted strongly with an epitope in peptide 66–85. Other epitopes were recognized weakly by some varicella or zoster
sera. More sera need to be tested to assess the potential disease specificity of these epitopes. The neutralizing monoclonal
antibody (MAb) IF-B9 reacted with residues 71–90; however, another neutralizing MAb, SG1A, which bound to both gE(1–
134)–VLPs and gE(101–161)–VLPs did not bind to any peptide. The identification of immunodominant sequences of gE
will help toward the development of a subunit VZV vaccine. q 1995 Academic Press, Inc.
INTRODUCTION led to the recommendation that there should be a routine
vaccination program for healthy children (Lieu et al.,
Varicella-zoster virus (VZV) is the etiologic agent of 1994).
chickenpox (varicella) and shingles (zoster), and is a Active immunization currently involves the use of live
member of the family Herpesviridae. VZV is highly infec- vaccine strains and the Oka live varicella vaccine (Taka-
tious and is spread by airborne droplets. The initial site hashi et al., 1974) is produced commercially by several
of infection may be the conjunctiva, the upper respiratory companies. In various large, well-controlled trials, the
tract, or both. VZV becomes latent in dorsal root and live VZV vaccine has proved to be effective in inducing
cranial nerve ganglia with reactivation and recrudes- high and durable VZV-specific antibody and cell-medi-
cence as shingles in later life. This reactivation may be ated responses and protection against disease (Asano
caused by immunosuppression or other ill-defined mech- et al., 1985; Baba et al., 1977; Gershon et al., 1986, 1988).
anisms and is associated with depressed cell-mediated There are, however, several problems with the live vac-
immunity (Grose, 1982). In industrialized countries, chick- cine which have restricted its use; for example, there is
enpox is predominantly a childhood disease but it is good evidence that the vaccine virus may later reactivate
often a more severe disease if it occurs in adults and to cause zoster (particularly in immunosuppressed chil-
immunocompromised children (Gershon, 1975). It has dren); there are doubts with regard to the long-term effi-
been estimated that, worldwide, there may be 57 million cacy of the vaccine; and it is ineffective in children under
cases of chickenpox in children per year and an effective 6 months of age due to the presence of maternal antibod-
mass childhood vaccination program could reduce the ies (Kangro, 1990). It is evident that a low cost, safe, and
number of cases of chickenpox per year by 78% (Preblud potent subunit VZV vaccine would be highly advanta-
et al., 1985). A more recent cost–benefit analysis has geous over the present live vaccine and could be intro-
duced into mass vaccination programs for normal chil-
dren.1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (0)1865 781115. VZV virions are pleiomorphic and measure 180–200
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nm in diameter. The icosahedral nucleocapsid measures We devised a strategy, therefore, to identify the immu-
nodominant regions of gE using a recombinant particu-100 nm in diameter and is surrounded by a lipid envelope
which contains the viral glycoproteins. The VZV envelope late antigen production and presentation system, hybrid
Ty-VLPs, and Pepscan analysis. The particulate presen-glycoproteins have been classified as gE, gB, gH, gI, gC,
and gL depending upon their abundance and immunoge- tation system is based on the self-assembling properties
of a protein, p1, encoded by the TYA gene of the yeastnicity (Grose, 1990). The publication of the complete virus
sequence (Davison and Scott, 1986) has aided progress retrotransposon, Ty. When TYA is massively overex-
pressed, very high yields of virus-like particles (VLPs) cantoward elucidating the important protective antigens of
varicella in order to develop a subunit vaccine. The major be obtained (Adams et al., 1987a,b). By overexpressing
hybrid TYA:antigen genes in yeast, we have shown thatimmunoreactive proteins in Western blot analysis of sera
from patients with varicella and zoster are found in the the resulting p1 fusion proteins still assemble into parti-
cles. The result is a high yield of particulate, polyvalent78- to 114-kDa region, with other reactive proteins found
at 32, 36, 66, and 220 kDa. These reactive bands include antigen. These hybrid VLPs are potent immunogens, elic-
iting humoral and cell-mediated immunity when injectedthe envelope glycoproteins and the nucleocapsid com-
plex known as p32/p36 or assembly protein (Dubey et into experimental animals (Griffiths et al., 1991; Harris et
al., 1992; Mills et al., 1991) and humans (Martin et al.,al., 1988; Harper et al., 1988; Harper and Grose, 1989).
Antibodies to the glycoproteins, particularly gE, gB, and 1993). Because of their particulate nature, hybrid VLPs
can be purified using straightforward biophysical meth-gH, predominate after natural infection and vaccination
(Harper et al., 1990) and they can effectively neutralize ods resulting in substantial yields and high levels of pu-
rity (Burns et al., 1991).the virus (Arvin et al., 1986; Forghani et al., 1990; Keller
et al., 1984). Maternal antibodies are protective in young The approach we have taken to identify immunodomi-
nant regions of gE was to insert overlapping fragmentsbabies, further highlighting the role of antibody in protec-
tion. of the gE gene into our standard VLP yeast expression
system. The p1–gE fragment fusion proteins were thenIt is now well established that cell-mediated immunity
is a vital component for protection against primary vari- expressed in yeast and particle formation and antigenic-
ity assessed. The antigenicity was evaluated using seracella infection and against zoster and a cellular response
can be detected against the glycoproteins and against from individuals with recent chickenpox and zoster infec-
tions and also neutralizing mouse MAbs. Having definedthe immediate early protein IE62 in infected or vaccinated
individuals (reviewed in Arvin, 1992). In particular, gE, gH, the immunodominant fragment of gE using VLPs, the
position of linear B cell epitopes within that fragmentand IE62 have been shown to stimulate cell-mediated
immunity in humans and in guinea pigs (Giller et al., was then established by Pepscan analysis. Sera were
tested for reactivity against peptides of 20 amino acids1989; Arvin, 1994). Furthermore, immunization with IE62
protein protected guinea pigs against challenge (Sabella in length, overlapping by 15, representing the most anti-
genic fragment (residues 1–134) of gE.et al., 1993). One or more of these proteins may be re-
quired for an effective subunit vaccine.
gE is the most abundant and immunogenic of the virion MATERIALS AND METHODS
envelope glycoproteins (Keller et al., 1984; Weigle and
Cloning of gE DNA fragments from genomic VZV DNA
Grose, 1983). It is encoded by VZV gene 68 and the
by PCR
primary translation product of 73 kDa is processed to
the mature glycosylated form of 98 kDa. There is direct Fragments spanning the gE open reading frame were
generated from genomic DNA derived from VZV isolateevidence that gE induces both neutralizing antibodies
and T-helper cell responses (Arvin et al., 1986, 1987; H-551 (Harper et al., 1988). PCR was carried out in a
total volume of 50 ml with 200 ng template DNA, 16 pmolForghani et al., 1990; Hayward et al., 1989) and contains
epitopes recognized by CD4/ and CD8/ cytotoxic lym- of each primer, 1 mM each dNTP (Pharmacia) in PCR
buffer (10 mM KCl, 10 mM (NH4)2SO4 , 20 mM Tris–HClphocytes from VZV-infected individuals (Hayward et al.,
1989; Arvin, 1992, 1994). Virus neutralization has been [pH 8.8], 2 mM MgSO4) with 2 units VentRDNA polymer-
ase (New England Biolabs). Samples were amplified bystudied using panels of monoclonal antibodies (MAbs)
against gE and at least three distinct immunogenic do- an initial round of 957 denaturation (2 min), 557 annealing
(1 min), and 707 extension (5 min) followed by 30 roundsmains have been identified (Forghani et al., 1990). The
first contains two complement-dependent neutralizing of 957 for 1 min, 557 for 1 min, and 707 for 3 min with a
final 30-min step at 257. The PCR oligonucleotide primersepitopes. The second contains five complement-depen-
dent, overlapping epitopes and one nonneutralizing epi- were designed to incorporate an 8 base pair ‘‘stuffer
fragment’’ and either Bgl II or BamHI restriction endonu-tope. The third contains a complement-dependent (but
complement-enhanced) epitope. The location of these clease sites. The PCR products were visualized with
ethidium bromide after electrophoresis through a 1%epitopes has not been mapped.
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agarose gel and the bands were sized against uX174/ followed by size-exclusion chromatography as previously
described (Burns et al., 1991). This material is generallyHaeIII DNA (Promega Ltd.). The gE PCR fragments were
treated with proteinase K, digested with Bgl II and BamHI, between 80 and 95% pure.
and purified on a 1% agarose gel. The amplified DNA
was transferred by electroelution on to DEAE membrane
Viral antigen, human sera, and MAbs
(Schleicher and Schuell Ltd.; 0.45 mm; NA45) and recov-
ered by elution into high-salt buffer. VZV antigen was prepared from the H-551 VZV iso-
late. The virus was cultured in MRC5 cells and then
Construction of plasmids extracted using glycine/NaCl buffer (pH 9.6). Pooled
sera from 6 individuals with recent zoster infectionRecombinant plasmids were constructed by standard
(PZ6) and 17 individual sera from people with recentcloning procedures (Sambrook et al., 1989). The PCR
chickenpox or zoster infections were collected at St.fragments encoding gE fragments were inserted as Bgl II
Bartholomews Hospital and stored in aliquots at 0207.or Bgl II/BamHI cassettes into the multiple cloning site
The murine MAb IF-B9 is specific for gE and was ob-of the modified transfer vector pSP64 (Promega). Frag-
tained from Dr. J. Taylor-Weideman (University of Cam-ment 2 of gE contains an internal Bgl II site and was
bridge). The neutralizing murine MAb SG1A was pur-therefore cloned as two separate fragments (see Table
chased from VIRO Research Inc.1). Recombinant plasmids were identified by restriction
analysis and purified using QIAGEN columns (Hybaid).
The gE DNA fragments were then excised from the trans- SDS–PAGE and Western blot analysis
fer vector by digestion with Bgl II or Bgl II/BamHI, purified
from an agarose gel as previously described and ligated Denaturing SDS–PAGE was performed according to
to the truncated TYA gene of vector pOGS40. The expres- Laemmli (1970) using the Mini-protean II (Bio-Rad) appa-
sion of this vector in yeast is under the control of a PGK- ratus. Gels contained 12.5% acrylamide/bisacrylamide,
GAL hybrid inducible promoter (Adams et al., 1991). The ratio 37:1 (Sigma, A-6050). The samples were diluted (1:1)
nucleotide sequence of the constructions were con- in loading buffer and boiled for 3–5 min. The denatured
firmed by sequencing using Sequenase (United States samples were applied on to the gel at concentrations of
Biochemical). 0.5–5 mg/lane. The electrophoresis was performed at
200 V. The gel was stained with Coomassie blue and
Production of hybrid gE–VLPs in yeast then destained in methanol (20% v/v) and glacial acetic
acid (10% v/v). Molecular weight markers were used toSaccharomyces cerevisiae strain MC2 was trans-
facilitate the calculation of the molecular weights for theformed with the p1–gE fragment-expressing plasmids as
unknown proteins.previously described (Burns et al., 1991). Single colonies
Proteins separated by SDS–PAGE were transferredwere purified by streaking onto fresh plates. The trans-
on to a nitrocellulose membrane (Schleicher and Schuell;formed cells were grown selectively in 50 ml SC–glc
0.45 m; BA85) using a wet Western blotter (Mini-proteanmedium at 307 for 24 hr with agitation. This was used to
II, Bio-Rad). A constant current of 100 V for 1 hr wasinnoculate 500 ml SC–glc medium supplemented with
applied to transfer the proteins. The membranes were10 g/liter galactose until a cell density of 4–6 1 107/ml
then thoroughly washed with distilled water and incu-was reached (18 hr). The yeast cells were harvested
bated with blocking buffer [PBS containing 5% (w/v)at 4200 rpm (5000 g) for 20 min, washed three times in
skimmed milk (Marvel)] for 1 hr at room temperature (RT).TEN buffer [0.1 M NaCl, 10 mM Tris–HCl (pH 8.0) con-
The membranes were washed three times (5 min eachtaining 1 mM EDTA (pH 8.0)] and VLPs were released
wash) with PBS/Tween 20 (0.05% v/v) and incubated forby vortexing cells with glass beads (40 mesh; BDH). The
1 hr at RT with test sera or MAb diluted in blocking buffer.clarified homogenate was spun at 9000 rpm (11,000 g)
Then, the membranes were washed, as before, and incu-for 20 min and particles partially purified by centrifugation
bated with peroxidase-labeled anti-human or anti-mouseat 100,000 rpm (541,000 g) for 17 min on to a 60% sucrose
IgG conjugate (Sigma) diluted 1/50 in blocking buffer. Thecushion with a second centrifugation for 40 min onto a
membranes were washed and developed with a solution35–60% cushion. The VLPs were resuspended in sterile
containing nickel chloride (2% w/v, 0.3 ml), 3,3*-diamino-PBS. The formation of gE fragment–VLPs was deter-
benzidine (1 mg/ml, 1.5 ml), hydrogen peroxide (0.002%mined by SDS–PAGE analysis. This material is referred
v/v, 30 ml) in PBS (13.2 ml). The reaction was stoppedto as ‘‘spin-prep’’ VLPs and the purity is generally be-
with distilled water and the membranes were dried intween 40 and 60%.
the dark. The intensity of the bands was scored fromThe hybrid gE fragment–VLPs selected for further
// to 0 after subtracting any nonspecific reactivity withstudies were produced at 12 liter scale fermentation and
purified by fractionation on a 35–60% sucrose gradient control nonhybrid VLPs.
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Enzyme-linked immunosorbent assay (ELISA) 8 (36–55): DDFHTDEDKLDTNSVYEPYY
9 (41–60): DEDKLDTNSVYEPYYHSDHA
Ninety-six-well plates (Nunc Immunoplate II) were 10 (46–65): DTNSVYEPYYHSDHAESSWV
coated with VZV antigen, control antigen, or purified gE 11 (51–70): YEPYYHSDHAESSWVNRGES
fragment–VLPs (5 mg/ml) diluted in coating buffer (car- 12 (56–75): HSDHAESSWVNRGESSRKAY
bonate/bicarbonate buffer, 0.05 M, pH 9.6) and incubated 13 (62–81): SSWVNRGESSRKAYDHNSPY
overnight at 47. The plates were washed three times with 14 (66–85): NRGESSRKAYDHNSPYIWPR
PBS/Tween 20 and then incubated with twofold dilutions 15 (71–90): SRKAYDHNSPYIWPRNDYDG
of sera or MAbs (1:100 starting dilution) in duplicate for 16 (76–95): DHNSPYIWPRNDYDGFLENA
2 hr at RT. The plates were washed as before. The bound 17 (81–100): YIWPRNDYDGFLENAHEHHG
antibodies were detected with either peroxidase-labeled 18 (86–105): NDYDGFLENAHEHHGVYNQG
anti-human or anti-mouse IgG conjugate (Sigma) after 19 (91–110): FLENAHEHHGVYNQGRGIDS
incubation for 2 hr at RT. Sera and conjugate (1/1000) 20 (96–115): HEHHGVYNQGRGIDSGERLM
dilutions were prepared in PBS/Tween 20 containing ca- 21 (101–120): VYNQGRGIDSGERLMQPTQM
sein (2% w/v). The plates were washed, as above, and a 22 (106–125): RGIDSGERLMQPTQMSAQED
fresh substrate solution containing H2O2 and 2,2*-azi- 23 (111–130): GERLMQPTQMSAQEDLGDDT
nobis(3-ethylbenzthiazolinesulfonic acid) in citrate/phos- 24 (116–135): QPTQMSAQEDLGDDTGIHVI
phate buffer (0.05 M, pH 4.2) was prepared and immedi-
ately added to the plates. After 15 min, the reaction was
RESULTS
stopped by addition of sodium fluoride (2.5% w/v). The
optical density values were measured spectrophotomet- Formation of hybrid gE fragment–VLPs
rically at 405 nm. The reactivity of the sera and MAbs
A series of vectors for the production of gE fragment–were scored from // to 0 after subtracting any nonspe-
VLPs in yeast was constructed (Table 1). gE DNA frag-cific reactivity with control nonhybrid VLPs.
ments were inserted into the unique BamHI site of
pOGS40, the Ty p1 expression vector (Adams et al.,Inhibition ELISA
1991). The resulting plasmids were used to transform
Pooled zoster sera, PZ6 at 1/200 dilution was incu- yeast and the expression of fusion proteins induced in
bated with VZV antigen or gE fragment–VLPs (200 mg/ the presence of galactose. The cells were then homoge-
ml) overnight at 47 followed by centrifugation at 3000 rpm nized and the debris was removed by centrifugation. The
(1000 g) for 30 min. The supernatants were transferred to supernatant was then centrifuged onto a sucrose cush-
ELISA plates previously coated with VZV antigen, control ion and the deposit (VLPs) was resuspended and centri-
antigen, or gE fragment –VLPs. Direct ELISA was then fuged again onto a second sucrose gradient. During this
performed, as described. procedure VLPs, but not monomeric fusion protein or
yeast proteins, pass through and are partially purified.
Pepscan analysis Samples from this spin-prep procedure were run on
SDS–PAGE gels to confirm that fusion proteins of theTwenty-four synthetic peptides were synthesized by
correct size were present. The expression of p1-carryingthe multiple peptide system (ZENECA Ltd.). The 20-mer
fragments 1, 2a, 2b, and 3 produced fusion proteins thatpeptides covered the 1–135 gE VZV sequence and over-
assembled into hybrid VLPs, while the expression of p1lapped by 15 amino acids. The peptides were diluted to
carrying the other fragments produced no (fragments 430–40 mg/ml in coating buffer (pH 9.6) and ELISA plates
were incubated overnight at 47 with 50 ml/well. Each pep-
tide was coated in quadruplicate. Direct ELISA was then
TABLE 1
performed as described above. Significant reactivity was
Expression of VZV gE Fragment–VLPs in Yeastassessed by defining an arbitrary cutoff value for each
serum or MAb.
Plasmid gE fragment Amino acids VLP formation
The peptides corresponded to the following se-
quences: pOGS1208 1 1–134 ///
pOGS1207 2a 101–161 ///
1 (1–20): MGTVNKPVVGVLMGFGIITG pOGS1209 2b 161–233 ///
pOGS1210 3 201–333 //2 (6–25): KPVVGVLMGFGIITGTLRIT
pOGS1211 4 303–435 03 (11–30): VLMGFGIITGTLRITNPVRA
pOGS1212 5 402–536 //04 (16–35): GIITGTLRITNPVRASVLRY
pOGS1213 6 506–623 /
5 (21–40): TLRITNPVRASVLRYDDFHT
6 (26–45): NPVRASVLRYDDFHTDEDKL Note. The levels of VLP expression are indicated as follows: high
(///), medium (//), low (/), equivocal (//0), and negative (0).7 (31–50): SVLRYDDFHTDEDKLDTNSV
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TABLE 2
Summary of Antigenicity of VZV gE Fragment–VLPs
Western blot ELISA
Human sera MAb Human sera MAb
VLP Chickenpox a Zoster b IF-B9 SG1A Chickenpox a Zoster b IF-B9 SG1A
gE (1–134) // (100%) // (100%) // // // (100%) // (100%) // //
gE (101–161) // (100%) / (70%) 0 / / (100%) / (80%) 0 /
gE (161–233) 0 0 0 0 0 0 0 0
gE (201–333) //0 (14%) 0 0 0 //0 (14%) //0 (20%) 0 0
Note. Strong (//), medium (/), weak (//0), and negative (0) antibody responses. Percentage positive sera in parentheses. Average response
of 7 chickenpox seraa and 10 zoster sera including a pool of 6 sera.b ND, not determined.
and 5) or low (fragment 6) levels of VLPs. Although VLPs preparations probed with PZ6 zoster serum pool and
MAb IF-B9. The bands above the dominant band onwere not produced for the last three fragments, sufficient
fusion protein was produced to enable antigenic analysis gE(1–134)–VLPs represent multimers of the p1 fusion
protein which have resisted the denaturing conditions.by Western blot using crude yeast cell lysates. The plas-
mids and the fragment of gE carried by each hybrid p1 Furthermore, the observed molecular weight of the mo-
nomeric p1–gE(1–134) fusion protein is approximatelyfusion protein are described in Table 1. gE(1–134)–VLPs,
gE(101–161)–VLPs, gE(161–233)–VLPs, and gE(201– 63 kDa, whereas the calculated molecular weight is ap-
proximately 57 kDa. These anomalies are characteristic333)–VLPs were produced at 12-liter scale and purified
as previously described (Burns et al., 1991). of the p1 protein by SDS–PAGE analysis (Burns et al.,
1991).
Antigenicity of gE fragment–VLPs By ELISA, the highest antibody reactivity for all the
zoster and chickenpox sera was again obtained usingTo identify the regions of the gE protein that are most
gE(1–134)–VLPs as the antigen (Table 2). All the chick-immunogenic in humans following VZV infection, the anti-
enpox and 80% of the zoster sera also reacted well withgenicity of the gE fragment:Ty-VLPs was analyzed by
gE(101–161)–VLPs and 3/17 sera reacted weakly withWestern blotting and ELISA, using serum samples from
gE(201–333)–VLPs. MAbs IF-B9 and SG1A showed veryindividuals with recent chickenpox (7 sera) and zoster (9
high reactivity with the sequence 1–134 of gE and SG1Asera) infections, a pooled serum from six individuals with
also reacted with gE(101–161)–VLPs, as in the Westernrecent zoster infection, and also two neutralizing MAbs.
blot analysis. Table 3 shows the optical density valuesTable 2 summarizes the reactivities of these samples on
from 17 donor sera tested by ELISA against VLPs car-the various VLP antigens. All the samples reacted with
rying the immunodominant fragment gE(1–134), in addi-the VZV antigen but not control antigen preparation by
tion to the VZV and control antigen preparations. The PZ6Western blotting.
serum was used as a positive control and pooled seraThe most intense serum antibody reactivity by Western
from three individuals, who had no history of chickenpoxblotting was obtained with gE(1–134)–VLPs for all the
or shingles, were used as negative control. The pooledchickenpox and zoster sera tested. All the chickenpox
PZ6 serum produced a higher reactivity against the con-and the majority of the zoster sera were also reactive
trol antigen (OD of 0.357) compared to the negative con-against gE(101–161)–VLPs but did not react significantly
trol serum, but showed a strong reactivity to the VZVwith the other two hybrid VLPs covering amino acids
antigen and the gE(1–134)–VLPs. All the sera reacted161–333 (apart from weak reactivity with one chickenpox
with the VZV antigen while 7/8 chickenpox and 7/9 zosterserum on gE(201–333)–VLPs) or the cell homogenates
sera reacted with the gE(1–134)–VLPs. None of thesefrom yeast transformed with pOGS1211–1213 (express-
sera reacted with nonhybrid control VLPs apart from PZ6ing fragments covering residues 303–623). The produc-
which showed some nonspecific reactivity (data nottion of p1 fusion protein in these yeast cell homogenates
shown).was confirmed by blotting with a MAb to the Ty p1 protein
In order to confirm that the antibodies binding to the(data not shown). The two gE-specific MAbs reacted
gE(1–134)–VLPs also bind to native VZV gE, the humanstrongly with gE(1–134) –VLPs and SG1A also reacted,
PZ6 serum was adsorbed with VZV antigen prior to test-to a lesser degree, with gE(101–161)–VLPs. Figure 1
ing in the ELISA assay on VZV antigen, control antigen,shows typical Western blots of hybrid and control VLPs,
VZV, and control (noninfected cell lysate extract) antigen and gE(1–134)–VLPs. The unabsorbed and preabsorbed
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cell epitopes in this region in more detail using pepscan
analysis. Ten human sera showing strong reactivity
against gE(1–134)–VLPs by ELISA (PZ6 zoster serum
pool, 4 zoster sera, and 5 chickenpox sera) and the two
MAbs IF-B9 and SG1A were analyzed in the pepscan
assay using overlapping peptides representing gE(1–
135). All the samples, except SG1A gave identifiable
peaks of activity and representative histograms of pep-
tide reactivity are shown in Fig. 2. For each epitope rec-
ognized, in most cases, three or four sequential peptides
were positive because B cell epitopes are generally 3–
6 amino acids in length. In some cases, however, individ-
ual peptides were positive at a weak level and this may
represent the peak peptide of a group of 3 or 4. Assuming
an epitope size of 6 amino acids, a 10-amino-acid se-
quence containing the epitope could be defined, con-
sisting of the last 5 amino acids of the peptide immedi-
ately prior to a triplet of positive peptides and the first 5
amino acids of the peptide immediately after the triplet.
However, where epitope reactivities overlapped, i.e., 4
or more peptides were positive, it was not possible to
resolve an epitope to less than 20 amino acids.
The pepscan results are summarized in Table 4 which
shows the most immunodominant sequences recognized
by the zoster and chickenpox sera and the MAb IF-B9.
An epitope in HEHHGVYNQG (residues 96–105 in pep-
tide 18) was detected by all chickenpox and zoster sera.
An epitope in LGDDTGIHVI (126–135 in peptide 24) was
detected by all chickenpox sera and 4/5 zoster sera and
TABLE 3
FIG. 1. Western blot analysis of gE fragment–VLPs with (a) PZ6
ELISA Optical Density Values from a Chickenpoxpooled zoster serum, 1/100 and (b) MAb IF-B9, 1/3000. Lane 1 contains
and Zoster Serum Donor Panelprestained molecular weight markers, lane 2 is control nonhybrid VLPs,
lane 3 is gE(1–134)–VLPs, lane 4 is gE(101–161)–VLPs, lane 5 is
VZV ControlgE(161–233)–VLPs, and lane 6 is gE(201–333)–VLPs. All were loaded
Serum tested antigen antigen gE (1–134)–VLPsat 500 ng. Lane 7 contains control (noninfected cell lysate extract)
antigen and lane 8 contains VZV antigen loaded at 5 mg.
Chickenpox 1 0.327 0.137 0.658
CP2 0.383 0.130 0.354
CP3 0.544 0.116 0.652
PZ6 sera showed very low reactivity against the control CP4 0.549 0.116 0.709
antigen (OD value0.2). In contrast, the antibody binding CP5 0.474 0.126 0.358
CP6 0.307 0.124 0.108of the PZ6 serum to VZV antigen and gE(1–134)–VLPs
CP7 0.446 0.154 0.508gave OD values of 1.0 which were strongly inhibited by
CP8 0.337 0.176 0.606preabsorption with VZV antigen (98% inhibition of binding
Zoster 1 0.651 0.110 0.305
against VZV antigen and 76% inhibition of binding against Z2 0.288 0.119 0.122
gE(1–134)–VLPs). Absorption of the serum with gE(1– Z3 0.878 0.132 0.485
Z4 1.273 0.115 1.741134)–VLPs did not affect reactivity against VZV antigen
Z5 1.166 0.112 1.603but completely inhibited reactivity against gE(1–134) –
Z6 0.607 0.127 0.193VLPs (data not shown).
Z7 0.999 0.196 0.664
Z8 0.902 0.163 0.664
Identification of linear immunodominant sites of Z9 0.899 0.168 1.018
gE(1–134) PZ6 (pool) 1.105 0.357 1.740
Negative (pool) 0.132 0.130 0.171
Having identified gE(1–134) as the main immunodomi-
Note. Samples tested at 1/100.nant region of gE, we then sought to identify the linear B
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FIG. 2. Pepscan analysis of (a) PZ6 pooled zoster serum, (b) zoster serum 5, (c) chickenpox serum 1, and (d) the IF-B9 MAb.
an epitope in residues 56–75 (peptide 12) was recog- separate assays. The MAb IF-B9 gave a clear pattern of
reactivity with three peptides only (Fig. 2) and recognizednized by 3/5 zoster and 2/5 chickenpox sera. An epitope
in SRKAYDHNSP (71–80 in peptide 14) was recognized an epitope in the sequence YIWPRNDYDG (81–90).
by all chickenpox sera but was not recognized by any of
the zoster sera. Very weak binding of some chickenpox DISCUSSION
sera to epitopes in peptides 8 (4/5 sera) and 1 (2/5 sera)
and some zoster sera to epitopes in peptides 15 (3/5 In order to identify the immunodominant regions of the
VZV gE membrane glycoprotein we have produced virus-sera), 11 (2/5 sera), 6 (2/5 sera), and 8 (1/5 sera) were
detected. One serum (Z4) gave a very high binding to like particles carrying overlapping fragments of the 73-
kDa polypeptide. This protein is modified to produce thepeptide 15 with no reactivity to flanking peptides in two
TABLE 4
Summary of Pepscan Data: Immunodominant Epitopes in gE (1–135) Detected by Zoster and Chickenpox Sera
Sera tested (Peptide) residues Sequence Sera reactivity Sera positive
Human chickenpox (24) 116–135 Q P T Q M S A Q E D L G D D T G I H V I All // 5/5
(14) 66–85 N R G E S S R K A Y D H N S P Y I W P R / to // 5/5
CP1, CP3, CP4 (18) 86–105 N D Y D G F L E N A H E H H G V Y N Q G //0 to / 5/5
CP7, CP8 (12) 56–75 H S D H A E S S W V N R G E S S R K A Y 0 to / 2/5
Human zoster (18) 86–105 N D Y D G F L E N A H E H H G V Y N Q G / to // 5/5
Z4, Z5, Z7, Z8, PZ6 (24) 116–135 Q P T Q M S A Q E D L G D D T G I H V I 0 to // 4/5
(12) 56–75 H S D H A E S S W V N R G E S S R K A Y 0 to / 3/5
Mouse MAb
IF-B9 (15) 71–90 S R K A Y D H N S P Y I W P R N D Y D G NA NA
Note. The residues shown in bold represent the shortest definable epitope. NA, not applicable. Serum reactivity, arbitrary scoring of ELISA
reactivity of sera on peptide-coated plates.
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mature glycosylated form of gE of 98 kDa, via intermedi- many bands in a cell-extracted VZV antigen preparation
by Western blot analysis (Harper et al., 1988) and thisates of 81 and 90 kDa (Grose, 1990). Six of the seven
plasmids expressing p1–gE fragment fusion proteins confirms that gE is not the only major antigen and there-
fore not the only potential vaccine candidate. All seraproduced hybrid VLPs in yeast, as assessed by spin-
prep analysis (see Materials and Methods). However, tested from individuals with recent chickenpox or zoster
infections reacted with the VZV antigen by ELISA and 14/three produced insufficient levels of VLPs for purification
but did generate sufficient p1–gE fusion protein for anti- 17 of these sera were also positive on gE(1–134)–VLPs.
Of the three that were negative, two also showed rela-genic analysis. It is not clear why plasmids expressing
p1 fused to sequences from the C-terminal of gE (resi- tively weak reactivity on the VZV antigen. The sera tested
in this study were taken within 4 months of infection.dues 303–623) produce low levels of protein and/or
failed to produce particles in yeast. The region 385–445 The time of sampling the sera following infection will
obviously effect the levels of anti-VZV antibody in thecontains 6 cysteine residues with two further cysteines at
positions 552 and 559. These may interfere with protein sera and it is conceivable, but unlikely, that the specificity
of the response to gE and other proteins may changerefolding and the subsequent protein–protein interac-
tions required for VLP assembly. Consistent with this with time. This possibility needs to be investigated.
To define the immunodominant sequences moreidea is the observation that transformation of yeast with
the plasmid expressing p1 fused to residues 303–435 closely, we analyzed 10 sera and 2 monoclonal antibod-
ies by pepscan on synthetic peptides covering residuescontaining 5 cysteine residues resulted in no detectable
VLP formation. There are other ill-defined features of the 1–135. Pepscan analysis revealed that the most immuno-
dominant region for human and mouse antibodies wasprotein sequence which may also affect the expression
levels of p1 fusion proteins and particle formation, for between residues 50 and 135. Three epitopes in se-
quences 56–75, 86–105, and 116–135 were recognizedexample, the hydrophobicity of the sequence.
The gE protein can be divided into an extracellular by most chickenpox and zoster sera, with the epitope in
86–105 (HEHHGVYNQG) being recognized by all seradomain which spans residues 1–584 including a mem-
brane proximal region between residues 548 and 584, tested. All chickenpox, but no zoster sera reacted
strongly with an epitope in sequence 66–85 (SRKAYD-the transmembrane domain of gE between residues 585
and 601, and the cytoplasmic tail comprising residues HNSP), while epitopes in peptides 15, 11, and 6 were
recognized weakly by some zoster but not chickenpox602–623. The sequence of gE displays many features in
common with sequences of many cell surface receptors; sera. It is not clear if these epitopes are chickenpox or
zoster-specific and more sera will have to be tested tofor example, the TNF-like receptors and indeed the gE
molecule bind human IgG via its Fc region (Litwin et al., evaluate this. It may also be the case that testing further
sera may reveal additional epitopes. A neutralizing1992). One would expect, therefore, that the extracellular
domain would contain the immunodominant region(s) mouse MAb IF-B9 reacted with sequence 71–90 and
the epitope is within the sequence YIWPRNDYDG. Thissince this is the domain of gE on the virus and on VZV-
infected cells which would interact with the immune sys- epitope appears to be distinct from those recognized by
the human sera tested, although smaller peptides willtem. In antigenicity studies, using human sera from indi-
viduals who had recent chickenpox or zoster infections, be required to precisely define individual epitopes for
both human sera and MAbs. The difference in epitopethis supposition proved to be the case and the most
antigenic fragments of gE expressed on VLPs were resi- recognition between mice and humans may be related
to the form of antigen presentation; i.e., live infection indues 1–134 and 101–161. Two neutralizing MAbs, IF-B9
and SG1A, also reacted with VLPs carrying residues 1 – humans versus active immunization with adjuvant in
mice. Surprisingly, the MAb SG1A did not bind to any134 and we have also observed that another gE-specific
MAb, 3B3 (Grose et al., 1983) also reacts with gE(101 – peptide even though it bound strongly to gE(1–134) –
VLPs and, to a lesser degree, to gE(101–161)–VLPs.161)–VLPs (data not shown). Therefore, the region 1 –
161 is immunodominant and little or no antigenicity was This MAb reacted well with native gE in the VZV antigen
preparation and it may recognize a conformational orobserved to the remainder of gE (residues 161–623) as-
sessed by Western blot and ELISA of the hybrid VLPs or discontinuous epitope which is present in gE(1–134) –
VLPs but not represented by the set of linear 20-merby Western blot analysis of cell homogenates containing
p1–gE fragment fusion protein. peptides which overlap by 15.
The mapping studies have identified sequences in gEThe reactivity of serum antibodies against gE(1–134) –
VLPs could be absorbed using VZV antigen containing which contain the immunodominant B cell epitopes and
these may be useful in a human prophylactic vaccinenative gE. However, preincubation of a pool of zoster
sera with gE(1–134)–VLPs did not significantly diminish against chickenpox and possibly zoster infections. Stud-
ies are currently continuing to define these epitopes pre-its reactivity with VZV antigen by ELISA. This is not sur-
prising since this serum and most zoster sera react with cisely and to answer the most important question as to
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for Gene Expression’’ (M. Collins, Ed.), Vol. 8, pp. 277–285. Humanawhether antibodies recognizing the human epitopes on
Press, Clifton, NJ.gE are neutralizing. VLPs carrying the MAb IF-B9-defined
Davison, A. J., and Scott, J. E. (1986). The complete DNA sequence ofneutralizing epitope or one or more of the human B cell varicella-zoster virus. J. Gen. Virol. 67, 1759–1816.
epitopes may be potential VZV vaccine candidates. We Dubey, L., Steinberg, S. P., La Russa, P., Oh, P., and Gershon, A. A.
are also assessing the immunogenicity of gE(1–134)– (1988). Western blot analysis of antibody to varicella-zoster virus. J.
Infect. Dis. 157, 882–888.VLPs in experimental animals in terms of both neutraliz-
Forghani, B., Dupuis, K., and Schmidt, N. J. (1990). Epitopes functionaling antibody responses and cellular immune responses.
in neutralisation of varicella-zoster virus. J. Clin. Microbiol. 28, 2500–Using the 20-mer synthetic peptides representing resi-
2506.
dues 1–135 it will be possible to detect and map epi- Gershon, A. A. (1975). Varicella in mother and infant: A problem old
topes for proliferative T cell responses and cytotoxic T and new. In ‘‘Infections of the Fetus and the Newborn Infant’’ (S.
Krugman and A. A. Gershon, Eds.), pp. 79–95. A. R. Liss, New York.cell responses in inbred mice. We have shown previously
Gershon, A. A., Steinberg, S. P., and Gelb, L. (1986). The NIAID Varicellathat unadjuvanted hybrid VLPs can induce both types of
Vaccine Collaborative Study Group: Live attenuated varicella vaccineresponses to viral antigens (Harris et al., 1992; Layton et
use in immunocompromised children and adults. Pediatrics 78, 757–al., 1993). It is hoped that these studies will lead to a 762.
rationally designed subunit vaccine against VZV infec- Gershon, A. A., Steinberg, S. P., La Russa, P., Ferrara, A. A., Ham-
tions. merschlag, M., and Gelb, L. (1988). The NIAID Varicella Vaccine
Collaborative Study Group: Immunisation of healthy adults with live
attenuated varicella vaccine. J. Infect. Dis. 158, 132–137.
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